Cure8 research brief
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring. Patients and clinicians may see new options or monitoring tools on the horizon.
Clinicians, IBD researchers, adult and pediatric patients with IBD, and caregivers—especially those interested in perianal disease management, novel biologics/JAK/IL‑23 therapies, surgical strategy for ileal Crohn’s, and technology-enabled disease assessment.
This conference review summarizes selected late-breaking and practice-relevant studies presented at ECCO 2026. Key clinical trial mentions include phase 3 pediatric vedolizumab in UC, phase 2 picankibart in UC, regenerative fistula data for AVB-114 in perianal CD, and IL‑23 and JAK inhibitor data in therapy‑exposed populations.
Technology and monitoring advances reported include transperineal ultrasound for early steroid nonresponse detection in acute severe UC and multimodal AI for Mayo endoscopic scoring. Surgical data include 10‑year LIR!C follow-up supporting early surgery as a strategy in selected uncomplicated ileal CD.
A prevention study tested a whole‑food diet in first‑degree relatives at risk. The review is an expert appraisal emphasizing preliminary and practice‑influencing data; many findings are from extension, phase 2, or real‑world analyses and will need broader comparative or practice‑embedded studies before changing standard care.
This article is an abstracted review of conference presentations (structured content depth: abstract). Several items reported are preliminary (phase 2, extension, or real‑world analyses) and require larger comparative studies or peer‑reviewed full reports before routine clinical adoption.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
